<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>SB 546 (Edition 1)</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Times New \(W1\)";}
@font-face
	{font-family:IDAutomationHC39M;
	panose-1:2 0 5 9 0 0 0 2 0 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.25pt;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:23.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.MsoLineNumber
	{font-family:"Times New Roman",serif;}
p.LMSBase, li.LMSBase, div.LMSBase
	{mso-style-name:LMSBase;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aArticle, li.aArticle, div.aArticle
	{mso-style-name:aArticle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aArticleTitle, li.aArticleTitle, div.aArticleTitle
	{mso-style-name:aArticleTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBase, li.aBase, div.aBase
	{mso-style-name:aBase;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBillSection, li.aBillSection, div.aBillSection
	{mso-style-name:aBillSection;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock1, li.aBlock1, div.aBlock1
	{mso-style-name:aBlock1;
	mso-style-link:"aBlock1 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock2, li.aBlock2, div.aBlock2
	{mso-style-name:aBlock2;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock3, li.aBlock3, div.aBlock3
	{mso-style-name:aBlock3;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock4, li.aBlock4, div.aBlock4
	{mso-style-name:aBlock4;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock5, li.aBlock5, div.aBlock5
	{mso-style-name:aBlock5;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aChapter, li.aChapter, div.aChapter
	{mso-style-name:aChapter;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aHeading, li.aHeading, div.aHeading
	{mso-style-name:aHeading;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aLongTitle, li.aLongTitle, div.aLongTitle
	{mso-style-name:aLongTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	text-transform:uppercase;}
p.aMargin1, li.aMargin1, div.aMargin1
	{mso-style-name:aMargin1;
	mso-style-link:"aMargin1 Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aMargin2, li.aMargin2, div.aMargin2
	{mso-style-name:aMargin2;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aPart, li.aPart, div.aPart
	{mso-style-name:aPart;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSection, li.aSection, div.aSection
	{mso-style-name:aSection;
	mso-style-link:"aSection Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSP, li.aSP, div.aSP
	{mso-style-name:aSP;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.aSPComment, li.aSPComment, div.aSPComment
	{mso-style-name:aSPComment;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	color:red;
	display:none;
	font-weight:bold;}
p.aSPFunds1, li.aSPFunds1, div.aSPFunds1
	{mso-style-name:aSPFunds1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPFunds2, li.aSPFunds2, div.aSPFunds2
	{mso-style-name:aSPFunds2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPFundsHeading1, li.aSPFundsHeading1, div.aSPFundsHeading1
	{mso-style-name:aSPFundsHeading1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSPFundsHeading2, li.aSPFundsHeading2, div.aSPFundsHeading2
	{mso-style-name:aSPFundsHeading2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSPHeading, li.aSPHeading, div.aSPHeading
	{mso-style-name:aSPHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.nonumber, li.nonumber, div.nonumber
	{mso-style-name:nonumber;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPHeadingLine, li.aSPHeadingLine, div.aSPHeadingLine
	{mso-style-name:aSPHeadingLine;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.ASPlist, li.ASPlist, div.ASPlist
	{mso-style-name:ASPlist;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.5in;
	margin-bottom:.0001pt;
	text-indent:-1.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPRequestedBY, li.aSPRequestedBY, div.aSPRequestedBY
	{mso-style-name:aSPRequestedBY;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";}
p.aSPTitle, li.aSPTitle, div.aSPTitle
	{mso-style-name:aSPTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	text-transform:uppercase;
	font-weight:bold;}
p.aSubChapter, li.aSubChapter, div.aSubChapter
	{mso-style-name:aSubChapter;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSubPart, li.aSubPart, div.aSubPart
	{mso-style-name:aSubPart;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aTitle, li.aTitle, div.aTitle
	{mso-style-name:aTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.cHistoryNote
	{mso-style-name:cHistoryNote;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
p.TOCPageHeader, li.TOCPageHeader, div.TOCPageHeader
	{mso-style-name:TOCPageHeader;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSPSubTitle, li.aSPSubTitle, div.aSPSubTitle
	{mso-style-name:aSPSubTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSPHeadingMiscellaneous, li.aSPHeadingMiscellaneous, div.aSPHeadingMiscellaneous
	{mso-style-name:aSPHeadingMiscellaneous;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aDistrict, li.aDistrict, div.aDistrict
	{mso-style-name:aDistrict;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.aBlock1Char
	{mso-style-name:"aBlock1 Char";
	mso-style-link:aBlock1;
	font-family:"Times New Roman",serif;}
span.aMargin1Char
	{mso-style-name:"aMargin1 Char";
	mso-style-link:aMargin1;
	font-family:"Times New Roman",serif;}
span.aSectionChar
	{mso-style-name:"aSection Char";
	mso-style-link:aSection;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:10.0pt;
	line-height:115%;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 11.0in;
	margin:.6in .9in .5in 1.2in;}
div.WordSection1
	{page:WordSection1;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=nonumber align=center style='margin-top:24.0pt;text-align:center'><b>GENERAL
ASSEMBLY OF NORTH CAROLINA</b></p>

<p class=nonumber align=center style='margin-top:3.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-align:center'><b>SESSION 2019</b></p>

<p class=nonumber align=left style='text-align:left'><b>S                                                                                                                                                     1</b></p>

<p class=nonumber align=center style='text-align:center'><b>SENATE BILL 546</b></p>

<p class=nonumber align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=nonumber align=center style='text-align:center'><b>&nbsp;</b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=0
 style='width:6.55in;margin-left:-5.75pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=527 colspan=2 valign=top style='width:395.25pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-bottom:6.0pt;text-align:left'>Short
  Title:      Opioid Epidemic Response Act.</p>
  </td>
  <td width=102 valign=top style='width:76.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=right style='margin-bottom:6.0pt;text-align:right'>(Public)</p>
  </td>
 </tr>
 <tr>
  <td width=96 valign=top style='width:71.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:left'>Sponsors:</p>
  </td>
  <td width=533 colspan=2 valign=top style='width:399.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'>Senator J. Davis (Primary Sponsor).</p>
  </td>
 </tr>
 <tr>
  <td width=96 valign=top style='width:71.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:left'>Referred to:</p>
  </td>
  <td width=533 colspan=2 valign=top style='width:399.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'>Rules and Operations of the Senate</p>
  </td>
 </tr>
 <tr height=0>
  <td width=96 style='border:none'></td>
  <td width=431 style='border:none'></td>
  <td width=102 style='border:none'></td>
 </tr>
</table>

<p class=nonumber align=center style='margin-top:6.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'>April 3, 2019</p>

<p class=aBase align=center style='text-align:center'><span style='color:black'>A
BILL TO BE ENTITLED</span></p>

<p class=aLongTitle><span style='font-family:"Times New Roman",serif;
color:black'>AN ACT removing the requirement that buprenorphine prescribers
register with the state, in addition to registering with the federal
government; decriminalizing the use of drug testing equipment to detect
contaminants; broadening the objectives of syringe exchange programs to
encompass reducing the number of drug overdoses in the state AND REMOVING THE
BAN ON THE USE OF STATE FUNDS TO PURCHASE CERTAIN SUPPLIES; adding reporting
requirements for gabapentin and naloxone hydrochloride to the controlled
substances reporting system; requiring prescribers to check the controlled
substances reporting system when prescribing benzodiazepines; clarifying the
role of the state opioid treatment authority; establishing a state opioid
treatment authority fund; and establishing an opioid treatment program central
registry fee.</span></p>

<p class=aBase><span style='color:black'>The General Assembly of North Carolina
enacts:</span></p>

<p class=aBase><span style='color:black'>&nbsp;</span></p>

<p class=aHeading><span style='color:black'>PART I. ELIMINATION OF STATE
REGISTRATION REQUIREMENT FOR BUPRENORPHINE PRESCRIBERS</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 1.1.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;101(a1) is repealed.</span></p>

<p class=aBase><span style='color:black'>&nbsp;</span></p>

<p class=aHeading><span style='color:black'>PART II. DECRIMINALIZATION OF DRUG
TESTING EQUIPMENT USED TO DETECT CONTAMINANTS IN CONTROLLED SUBSTANCES</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 2.1.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;113.22 is amended by adding a new
subsection to read:</span></p>

<p class=aMargin1><span style='color:black'>&quot;<u>(d)</u>      <u>Notwithstanding
the provisions of subsection (a) of this section, it is not unlawful for</u> <u>(i)
a person who introduces a controlled substance into his or her body, or intends
to introduce a controlled substance into his or her body, to knowingly use, or to
possess with intent to use, testing equipment for identifying or analyzing the
strength, effectiveness, or purity of that controlled substance; or (ii) a
governmental or nongovernmental organization that promotes scientifically
proven ways of mitigating health risks associated with drug use and other high&#8209;risk
behaviors to possess such testing equipment or distribute such testing
equipment to a person who intends to introduce a controlled substance into his
or her body.</u>&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 2.2.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;113.22A is amended by adding a new
subsection to read:</span></p>

<p class=aMargin1><span style='color:black'>&quot;<u>(c)</u>      <u>Notwithstanding
the provisions of subsection (a) of this section, it is not unlawful for (i) a
person who introduces a controlled substance into his or her body, or intends
to introduce a controlled substance into his or her body, to knowingly use, or to
possess with intent to use, testing equipment for identifying or analyzing the
strength, effectiveness, or purity of that controlled substance; or (ii) a
governmental or nongovernmental organization that promotes scientifically
proven ways of mitigating health risks associated with drug use and other high&#8209;risk
behaviors to possess such testing equipment or distribute such testing
equipment to a person who intends to introduce a controlled substance into his
or her body.</u>&quot;</span></p>

<p class=aBase><span style='color:black'>&nbsp;</span></p>

<p class=aHeading>PART III. BROADENING THE OBJECTIVES OF SYRINGE EXCHANGE PROGRAMS
TO ENCOMPASS REDUCING THE NUMBER OF DRUG OVERDOSES IN THE STATE AND REMOVING
THE BAN ON THE USE OF STATE FUNDS TO PURCHASE CERTAIN SUPPLIES.</p>

<p class=aBillSection><b>SECTION 3.1.</b>  G.S.&nbsp;90&#8209;113.27 reads as
rewritten:</p>

<p class=aSection><span style='font-weight:normal'>&quot;</span>§ 90&#8209;113.27. 
Needle and hypodermic syringe exchange programs authorized; limited immunity.</p>

<p class=aMargin1>(a)        Any governmental or nongovernmental organization,
including a local or district health department or an organization that
promotes scientifically proven ways of mitigating health risks associated with
drug use and other high&#8209;risk behaviors, may establish and operate a
needle and hypodermic syringe exchange program. The objectives of the program
shall be to do all of the following:</p>

<p class=aBlock1>(1)        Reduce the spread of HIV, AIDS, viral hepatitis,
and other bloodborne diseases in this State.</p>

<p class=aBlock1>(2)        Reduce needle stick injuries to law enforcement
officers and other emergency personnel.</p>

<p class=aBlock1>(3)        Encourage individuals who <s>inject </s><u>use </u>drugs
<u>illicitly </u>to enroll in evidence&#8209;based treatment.</p>

<p class=aBlock1><u>(4)</u>        <u>Reduce the number of drug overdoses in
this State.</u></p>

<p class=aMargin1>(b)        Programs established pursuant to this section
shall offer all of the following:</p>

<p class=aBlock1>…</p>

<p class=aBlock1>(2)        Needles, hypodermic syringes, and other injection
supplies at no cost and in quantities sufficient to ensure that needles,
hypodermic syringes, and other injection supplies are not shared or reused. <s>No
State funds may be used to purchase needles, hypodermic syringes, or other
injection supplies.</s></p>

<p class=aBlock1>….&quot;</p>

<p class=aBase><span style='color:black'>&nbsp;</span></p>

<p class=aHeading><span style='color:black'>PART IV. REVISIONS TO THE
CONTROLLED SUBSTANCES REPORTING SYSTEM</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 4.1.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;113.72 reads as rewritten:</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 90&#8209;113.72.  Definitions.</span></p>

<p class=aMargin1><span style='color:black'>The following definitions apply in
this Article:</span></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>Benzodiazepine. – A psychoactive drug whose core
chemical structure is the fusion of a benzene ring and a diazepine ring and
works on the central nervous system, acting selectively on gamma&#8209;aminobutyric
acid type A receptors in the brain.</u></span></p>

<p class=aBlock1><s><span style='color:black'>(1)</span></s><u><span
style='color:black'>(1a)</span></u><span style='color:black'> Commission. – The
Commission for Mental Health, Developmental Disabilities, and Substance Abuse
Services established under Part 4 of Article 3 of Chapter 143B of the General
Statutes.</span></p>

<p class=aBlock1><span style='color:black'>….&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 4.2.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;113.73(a) reads as rewritten:</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 90&#8209;113.73.  Requirements for controlled substances
reporting system; civil penalties for failure to properly report.</span></p>

<p class=aMargin1><span style='color:black'>(a)        The Department shall
establish and maintain a reporting system of prescriptions for all Schedule II
through V controlled <s>substances. </s><u>substances, and for gabapentin and
naloxone hydrochloride. </u>Each dispenser shall submit the information in
accordance with transmission methods and frequency established by rule by the
Commission. The Department may issue a waiver to a dispenser who is unable to
submit prescription information by electronic means. The waiver may permit the
dispenser to submit prescription information by paper form or other means,
provided all information required of electronically submitted data is
submitted. The dispenser shall report the information required under this
section no later than the close of the next business day after the prescription
is delivered; however, dispensers are encouraged to report the information no
later than 24 hours after the prescription was delivered. The information shall
be submitted in a format as determined annually by the Department based on the
format used in the majority of the states operating a controlled substances
reporting system. In the event the dispenser is unable to report the
information within the time frame required by this section because the system
is not operational or there is some other temporary electrical or technological
failure, this inability shall be documented in the dispenser's records. Once
the electrical or technological failure has been resolved, the dispenser shall
promptly report the information.&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 4.3.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;113.74C reads as rewritten:</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 90&#8209;113.74C.  Practitioner use of controlled
substances reporting system; mandatory reporting of violations.</span></p>

<p class=aMargin1><span style='color:black'>(a)        Prior to initially
prescribing a targeted controlled substance <u>or a benzodiazepine </u>to a
patient, a practitioner shall review the information in the controlled
substances reporting system pertaining to the patient for the 12&#8209;month
period preceding the initial prescription. For every subsequent three&#8209;month
period that the targeted controlled substance <u>or a benzodiazepine </u>remains
a part of the patient's medical care, the practitioner shall review the information
in the controlled substances reporting system pertaining to the patient for the
12&#8209;month period preceding the determination that the targeted controlled
substance <u>or a benzodiazepine </u>should remain a part of the patient's
medical care. Each instance in which the practitioner reviews the information
in the controlled substances reporting system pertaining to the patient shall
be documented in the patient's medical record. In the event the practitioner is
unable to review the information in the controlled substances reporting system
pertaining to the patient because the system is not operational or there is
some other temporary electrical or technological failure, this inability shall
be documented in the patient's medical record. Once the electrical or technological
failure has been resolved, the practitioner shall review the information in the
controlled substances reporting system pertaining to the patient and the review
shall be documented in the patient's medical record.</span></p>

<p class=aMargin1><span style='color:black'>(b)        A practitioner may, but
is not required to, review the information in the controlled substances
reporting system pertaining to a patient prior to prescribing a targeted
controlled substance <u>or a benzodiazepine </u>to the patient in any of the
following circumstances:</span></p>

<p class=aBlock1><span style='color:black'>(1)        The controlled substance
is to be administered to a patient in a health care setting, hospital, nursing
home, outpatient dialysis facility, or residential care facility, as defined in
G.S.&nbsp;14&#8209;32.2.</span></p>

<p class=aBlock1><span style='color:black'>(2)        The controlled substance
is prescribed for the treatment of cancer or another condition associated with
cancer.</span></p>

<p class=aBlock1><span style='color:black'>(3)        The controlled substance
is prescribed to a patient in hospice care or palliative care.</span></p>

<p class=aMargin1><span style='color:black'>….&quot;</span></p>

<p class=aBase><span style='color:black'>&nbsp;</span></p>

<p class=aHeading><span style='color:black'>PART V. CLARIFICATION OF THE ROLE
OF THE STATE OPIOID TREATMENT AUTHORITY; ESTABLISHMENT OF A STATE OPIOID
TREATMENT AUTHORITY FUND; AND ESTABLISHMENT OF AN OPIOID TREATMENT PROGRAM
CENTRAL REGISTRY FEE</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 5.1.</span></b><span
style='color:black'>  G.S.&nbsp;122C&#8209;3, as amended by Section 1 of S.L.
2018&#8209;33, reads as rewritten:</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 122C&#8209;3.  Definitions.</span></p>

<p class=aMargin1><span style='color:black'>…</span></p>

<p class=aBlock1><u><span style='color:black'>(25a)</span></u><span
style='color:black'>    <u>&quot;Opioid treatment program&quot; means a program
or practitioner with a current and valid registration under 21 U.S.C. §
823(g)(1) that is engaged in dispensing opioid agonist medication for the
treatment of individuals with opioid use disorders.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(25b)</span></u><span
style='color:black'>    <u>&quot;Opioid Treatment Program Central Registry&quot;
or &quot;Central Registry&quot; means the computerized patient database
maintained by the State Opioid Treatment Authority to obtain patient
identifying information from participating opioid treatment programs for the
purposes of (i) allowing opioid treatment programs to avoid an individual's
concurrent enrollment in more than one opioid treatment program and (ii) to
provide a continuum of care.</u></span></p>

<p class=aBlock1><span style='color:black'>…</span></p>

<p class=aBlock1><span style='color:black'>(35c)    <u>&quot;State Opioid
Treatment Authority&quot; or &quot;SOTA&quot; means the section of the Division
of Mental Health, Developmental Disabilities, and Substance Abuse Services that
exercises the responsibility and authority within North Carolina for governing
the treatment of opioid use disorder with an opioid drug.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(35d)</span></u><span
style='color:black'>   &quot;State&quot; or &quot;Local&quot; Consumer Advocate
means the individual carrying out the duties of the State or Local Consumer
Advocacy Program Office in accordance with Article 1A of this Chapter.</span></p>

<p class=aBlock1><s><span style='color:black'>(35d)</span></s><u><span
style='color:black'>(35e)</span></u><span style='color:black'> &quot;State
Plan&quot; means the State Plan for Mental Health, Developmental Disabilities,
and Substance Abuse Services.</span></p>

<p class=aBlock1><s><span style='color:black'>(35e)</span></s><u><span
style='color:black'>(35f)</span></u><span style='color:black'>  &quot;State
resources&quot; means State and federal funds and other receipts administered
by the Division.</span></p>

<p class=aBlock1><span style='color:black'>….&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 5.2.</span></b><span
style='color:black'>  Chapter 122C of the General Statutes is amended by adding
a new Article to read:</span></p>

<p class=aArticle><span style='color:black'>&quot;<u>Article 2A.</u></span></p>

<p class=aArticleTitle><span style='color:black'>&quot;<u>State Opioid
Treatment Authority.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 122C&#8209;50.  Approval of opioid treatment programs.</span></u></p>

<p class=aMargin1><u><span style='color:black'>(a)</span></u><span
style='color:black'>        <u>Prospective opioid treatment programs shall apply
for and obtain approval by the State Opioid Treatment Authority prior to
seeking licensure by the Division of Health Service Regulation.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(b)</span></u><span
style='color:black'>        <u>The State Opioid Treatment Authority shall
approve or deny applications by prospective opioid treatment programs based
upon consideration of all the following criteria and any rules adopted by the
Commission regarding opioid treatment programs:</u></span></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>Capacity of the applicant to provide treatment
in compliance with applicable federal and State laws, regulations, and accepted
clinical standards of practice.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(2)</span></u><span
style='color:black'>        <u>Whether the applicant has prior experience operating
an opioid treatment program.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(3)</span></u><span
style='color:black'>        <u>History of adverse regulatory actions against
the applicant while employed by, or as a result of, ownership of an opioid
treatment program in North Carolina or another state.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(4)</span></u><span
style='color:black'>        <u>Written monitoring reports, compliance reports,
or incident reports concerning other opioid treatment programs operated by the
applicant or by an owner, principal, or affiliate of the applicant, issued within
the five&#8209;year period preceding the date of the application, whether in
North Carolina or in another state.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(5)</span></u><span
style='color:black'>        <u>History of suspension or revocation of, or
public action against, professional licenses or narcotic licenses of persons
proposed to be employed by the applicant's proposed opioid treatment program or
of the proposed sponsor of the opioid treatment program, whether in North
Carolina or in another state.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(6)</span></u><span
style='color:black'>        <u>The submission of false or misleading
information as part of an application for approval.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(7)</span></u><span
style='color:black'>        <u>Whether the applicant's proposed opioid
treatment program plans to accept health insurance, including health insurance
provided by the State or federal government.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(8)</span></u><span
style='color:black'>        <u>How the applicant's proposed opioid treatment
program would increase access to treatment in underserved regions.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(c)</span></u><span
style='color:black'>        <u>A prospective opioid treatment program may contest
a denial of its application by the State Opioid Treatment Authority by
commencing a contested case under Article 3 of Chapter 150B of the General
Statutes. In contesting the application denial, the prospective opioid
treatment program must file a petition for a contested case within 20 days
after the date the State Opioid Treatment Authority mails notice of the denial
to the applicant.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 122C&#8209;50.1.  Rules.</span></u></p>

<p class=aMargin1><u><span style='color:black'>(a)</span></u><span
style='color:black'>        <u>Using updated and nonstigmatizing language and
terminology regarding opioid use disorder treatment, the Commission shall adopt
or amend rules, as necessary, establishing standards for (i) the State Opioid
Treatment Authority's review, approval, and denial of prospective opioid
treatment programs and (ii) the licensure and operation of SOTA&#8209;approved
opioid treatment programs. The rules shall address all of the following in
order to improve the quality of, and access to, care in opioid treatment
programs:</u></span></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>Minimum requirements for staff positions,
staffing ratios, and staff training.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(2)</span></u><span
style='color:black'>        <u>Minimum operating hours.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(3)</span></u><span
style='color:black'>        <u>Counseling requirements.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(4)</span></u><span
style='color:black'>        <u>Minimum requirements for admissions processes,
procedures to prevent diversion of medication, and use of the Controlled
Substances Reporting System and the Central Registry.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(5)</span></u><span
style='color:black'>        <u>Requirements for physical plant.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(6)</span></u><span
style='color:black'>        <u>Requirements for the provision of take&#8209;home
medications.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(7)</span></u><span
style='color:black'>        <u>Site visits by the State Opioid Treatment
Authority.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(8)</span></u><span
style='color:black'>        <u>Creation of a system for the approval of
medication units and requirements for the operation of medication units.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(9)</span></u><span
style='color:black'>        <u>Other changes in the interest of health and
safety, as determined by the Commission.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(b)</span></u><span
style='color:black'>        <u>The Commission is exempt from the requirements
of G.S.&nbsp;150B&#8209;21.4 with respect to the rules adopted under this
section.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 122C&#8209;50.2.  State Opioid Treatment Authority Fund.</span></u></p>

<p class=aMargin1><u><span style='color:black'>(a)</span></u><span
style='color:black'>        <u>The State Opioid Treatment Authority Fund is
established within the Department as an interest&#8209;bearing special revenue
fund. The Department shall administer the SOTA Fund. The Department shall not
use moneys in the Fund for any purpose other than to offset the cost of
operating the Opioid Treatment Program Central Registry. The SOTA Fund shall be
used to supplement and not supplant or replace existing State and local funding
available for these purposes.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(b)</span></u><span
style='color:black'>        <u>The Fund shall consist of the following:</u></span></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>All fees collected by the Department for the Opioid
Treatment Program Central Registry pursuant to G.S.&nbsp;122C&#8209;50.3.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(2)</span></u><span
style='color:black'>        <u>Any moneys appropriated to the SOTA Fund by the
General Assembly.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(3)</span></u><span
style='color:black'>        <u>Any money received from State, federal, private,
or other sources for deposit into the SOTA Fund.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(c)</span></u><span
style='color:black'>        <u>All interest that accrues to the SOTA Fund shall
be credited to the Fund. Any balance remaining in the SOTA Fund at the end of
any fiscal year shall remain in the Fund and shall not revert to the General
Fund.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 122C&#8209;50.3.  Opioid Treatment Program Central Registry;
annual fee.</span></u></p>

<p class=aMargin1><u><span style='color:black'>(a)</span></u><span
style='color:black'>        <u>The State Opioid Treatment Authority shall
require the participation of all opioid treatment programs in the Opioid Treatment
Program Central Registry. Opioid treatment programs shall submit data to the Central
Registry as directed by the State Opioid Treatment Authority.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(b)</span></u><span
style='color:black'>        <u>Beginning January 1, 2020, the Department shall
charge each opioid treatment program an annual fee in the amount of one thousand
six hundred dollars ($1,600) for participation in the Central Registry. One
hundred percent (100%) of each fee collected pursuant to this subsection shall
be credited to the State Opioid Treatment Authority Fund established in G.S.&nbsp;122C&#8209;50.2,
to be used to offset the cost of operating the Opioid Treatment Program Central
Registry. The Commission may by rule, and in consultation with the Secretary,
increase this fee by no more than the amount necessary to offset the cost of
operating the Central Registry.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(c)</span></u><span
style='color:black'>        <u>The fee authorized by this section is due and
payable by an opioid treatment program within seven days after the program is
granted final certification by the federal Substance Abuse and Mental Health
Services Administration to begin operating as an opioid treatment program. The Department
shall prorate the amount of this fee on a calendar year basis during the first
year an opioid treatment program participates in the Central Registry.</u>&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 5.3.</span></b><span
style='color:black'>  By May 1, 2020, the Commission for Mental Health,
Developmental Disabilities, and Substance Abuse Services shall amend or adopt
rules to address the areas prescribed by G.S.&nbsp;122C&#8209;50.1, as enacted
by this act.</span></p>

<p class=aBase><span style='color:black'>&nbsp;</span></p>

<p class=aHeading><span style='color:black'>PART VI. EFFECTIVE DATE</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 6.1.(a)</span></b><span
style='color:black'>  Sections 4.1 and 4.3 of this act are effective 30 days
after the date the State Chief Information Officer notifies the Revisor of
Statutes that (i) the upgrades to the Controlled Substances Reporting System
(CSRS) database described in subdivisions (1) and (2) of subsection (a) of
Section 12F.7 of S.L. 2016&#8209;94 have been completed and (ii) the upgraded
CSRS database is fully operational within the Department of Information
Technology and connected to the statewide health information exchange.</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 6.1.(b)</span></b><span
style='color:black'>  Section 4.2 of this act becomes effective January 1,
2020.</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 6.1.(c)</span></b><span
style='color:black'>  G.S.&nbsp;122C&#8209;50.2, as enacted by Section 5.2 of
this act, becomes effective July 1, 2019.</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 6.1.(d)</span></b><span
style='color:black'>  The remainder of this act is effective when it becomes
law.</span></p>

</div>

</body>

</html>
